Methods and compositions for bone formation
US-2015359852-A1 · Dec 17, 2015 · US
US10064896B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10064896-B2 |
| Application number | US-201414334318-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 17, 2014 |
| Priority date | Jul 17, 2014 |
| Publication date | Sep 4, 2018 |
| Grant date | Sep 4, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material (6) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material (10) that is dry and can be stored at room temperature for long periods of time. This powder (10) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture (20).
Opening claim text (preview).
What is claimed is: 1. An aqueous spinal disc regenerative composition suitable for injection, wherein the aqueous composition comprises: a hydrated composition comprising freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of: (i) providing normal human cadaveric intervertebral discs; (ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs; (iii) drying the nucleus pulposus; (iv) micronizing the dried nucleus pulposus by pulverizing in a cryomill at a low temperature into particles sized less than 400 microns; (v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv); and then (vi) mixing the freeze-dried micronized nucleus pulposus with the fluid thereby producing the hydrated composition. 2. The aqueous spinal disc regenerative composition of claim 1 wherein the freeze-dried micronized nucleus pulposus provided for mixing in step (vi) is in the form of a powder. 3. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized freeze-dried nucleus pulposus has proteoglycan molecules. 4. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized freeze-dried nucleus pulposus has been dried to less than 5% moisture content prior to being rehydrated. 5. The aqueous spinal disc regenerative composition of claim 1 wherein the aqueous composition further comprises one or more of the following: stem cells, micronized amnion, platelet-rich plasma, growth factors, genetically altered cells that produce glycosaminoglycans, collagen Type 1 and glucose. 6. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized material of dried nucleus pulposus has water absorbed by the proteoglycan molecules depleted from the freeze-dried nucleus pulposus. 7. An aqueous spinal disc regenerative composition suitable for injection, wherein the aqueous composition comprises: a hydrated composition comprising freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of: (i) providing normal human cadaveric intervertebral discs; (ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs; (iii) drying the nucleus pulposus; (iv) micronizing the dried nucleus pulposus by pulverizing in a cryomill at a low temperature into particles sized less than 400 microns; (v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv); (vi) mixing the freeze-dried micronized nucleus pulposus with the fluid thereby producing the hydrated composition; wherein the freeze-dried micronized nucleus pulposus provided for mixing in step (vi) is in the form of a powder; and mixing one or more of stem cells that are derived from marrow, fat, blood or interspinous ligaments; micronized amnion; platelet-rich plasma; and/or growth factors encapsulated in pharmacologically active microspheres, with the powdered freeze-dried micronized nucleus pulposus prior to step (vi), or with the hydrated composition after step (vi). 8. The composition of claim 1 wherein the normal human cadaveric intervertebral discs are intervertebral discs aseptically recovered from cadaveric spine segments from T9 to LS. 9. A composition consisting of: (a) a syringe or injectable device which is capable of being inserted into a damaged disc to be treated; and (b) a hydrated composition consisting of freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of: (i) providing normal human cadaveric intervertebral discs; (ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs; (iii) drying the nucleus pulposus; (iv) micronizing the dried nucleus pulposus by placing the dried material in a cryomill at low temperature and pulverizing the dried nucleus pulposus into particles sized less than 400 microns into a powder; (v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv); and then (vi) mixing the freeze-dried micronized nucleus pulposus with the fluid, thereby producing the hydrated composition and mixing one or more of stem cells that are derived from marrow, fat, blood or interspinous ligaments; micronized amnion; platelet-rich plasma; and/or growth factors encapsulated in pharmacologically active microspheres, with the powdered freeze-dried micronized nucleus pulposus prior to step (vi), or with the hydrated composition after step (vi); wherein the (b) hydrated composition with one or more stem cells is contained within the (a) syringe or injectable device; and wherein the (b) hydrated composition has a viscosity which permits it to flow through a cannula.
Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells · CPC title
for introducing fluid filler into bone or extracting it (A61B17/7097, A61B17/8833 take precedence) · CPC title
Cartilage, synovial fluid · CPC title
Flowable or injectable implant compositions · CPC title
Intervertebral or spinal discs, e.g. resilient (non-disc-shaped intervertebral inflatable pockets A61F2/441; non-disc-shaped intervertebral fusion implants A61F2/4455) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.